FDA Measures Naloxone Price Trend In Considering Wider Availability
This article was originally published in The Tan Sheet
Even though FDA cannot consider drug pricing, it gives research of naloxone sales to inform workshop on uptake and use. Amphastar’s naloxone prices are being scrutinized by state officials and a House member.
You may also be interested in...
FDA 'complete response' letter follows advisory committee's conclusion that the current naloxone approval standard is inadequate.
After ‘Clean’ User Fee Renewal, Will Programs Held Hostage Be Enough To Drive A Broader Reform Bill?
Continuing resolution will force lawmakers back to the bargaining table before year end. Orphan grants and pediatric exclusivity are among the programs left out of the short-term spending measure as Congressional Democrats seek leverage to add more policy riders.
Next US FDA Generics Leader Must Have ‘Frank Conversations’ With Colleagues, Industry, Former OGD Director Says
Susan Rosencrance, who helped negotiate GDUFA III, will take over as acting director of the Office of Generic Drugs following Sally Choe’s departure on 8 October. Former OGD head Uhl says the director needs to be the ‘number one advocate for the generic drug program inside the agency.’